Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
about
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsToolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccineExploiting virus-like particles as innovative vaccines against emerging viral infectionsCharacterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy.Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial.The development of a recombinant hepatitis E vaccine HEV 239.My passion for biologics: from active sites to life-saving and public health.Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.Evidences of Changes in Surface Electrostatic Charge Distribution during Stabilization of HPV16 Virus-Like Particles.The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron MicroscopyA human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58Construction and characterization of virus-like particles: a review.Bioengineering virus-like particles as vaccines.Recent progress in vaccination against human papillomavirus-mediated cervical cancer.Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles.Functional assessment and structural basis of antibody binding to human papillomavirus capsid.Cervical cancer: A comprehensive approach towards extermination.Forced degradation studies: current trends and future perspectives for protein-based therapeutics.Cervical cancer: A global health crisis.Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 PromoterStructural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization.Efficient inhibition of human papillomavirus 16 L1 pentamer formation by a carboxylatopillarene and a p-sulfonatocalixarene.In vitro monitoring of the formation of pentamers from the monomer of GST fused HPV 16 L1.Correlation of In Vivo and In Vitro Assay Results for Assessment of Free Radical Scavenging Activity of Green Tea Nutraceuticals.Escherichia coli-derived virus-like particles in vaccine development.High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.9-Valent human papillomavirus vaccine: a review of the clinical development program.Principles of vaccine potency assays.Non-human papillomaviruses for gene delivery in vitro and in vivo.
P2860
Q27013018-53C68F60-CE7E-4828-8A66-A8D0D5CDC632Q28730718-242DDBA0-0E3D-4071-B572-60D5E5BC5197Q29365799-6CFAA39D-598C-4FA7-85D1-3BF1DA14757EQ34033805-0D6ADF7C-41CC-4264-A658-281D059D488EQ34290684-C9661B04-AC90-4C3F-AB1E-657B449E5432Q34464464-D159CB89-8703-402F-A1B8-468710E573E3Q35886570-C80B4AB9-7093-4331-BF65-940E0916F709Q35887653-EB749417-67C2-4BA7-BE9F-9C12BBEE3D9EQ35925828-574D25EC-64CB-4E27-BF6B-EA2BBB0657DEQ36281141-B88C90F1-3A29-459C-AB48-CAD21E2B81E7Q36448778-A2071F68-97F6-40A2-95A7-EB21C5305372Q37712837-365D9DC3-7DB7-4C9F-B162-F2A3629B6CC7Q38045834-F75CD9C3-4167-468B-9818-B2F0DA93AD69Q38172045-6A4694C0-CF2B-49A4-9DD4-0A519366D1EDQ38370782-49C33996-F2BA-4040-9E92-FD3AB27A30D1Q38423724-26C83EA8-6CB6-4163-AFED-CD2BD9763DEEQ38671633-E1FD77DC-8707-4211-93ED-6CCAAE0160FEQ38748682-88838630-C53A-46D8-ABC0-31A2B5C7A94BQ38855242-A1B6F908-0856-4AB0-917D-E46AEE94E6FBQ39278591-EAF8D262-4797-443C-A847-0D585284C654Q41462631-4D72C5F9-FDC6-48A9-96EA-E898BDA96EE6Q41605239-8075B437-A242-4C39-A742-3C79825CDDE8Q42237434-844B18AC-8F9E-495B-A569-00EA81B452BBQ42276716-C780F67F-DC21-4379-BEC6-5A735EE4889CQ46535833-34DF856A-D37E-4FA6-A5EE-3E4045F0D74DQ47132009-527258A7-4226-4F57-9491-D450E234039CQ47136931-C159C30B-BA52-4D1A-9195-DD0B0E14F17EQ49687633-333C22F7-51F6-45E2-B3CB-1891346B4370Q50047834-23209299-2BD8-4FC5-88B6-86258D7EC7E3Q55415533-1E427DDF-BE73-42BB-B6C5-438B3E396AFD
P2860
Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Disassembly and reassembly of ...... rion-like antibody reactivity.
@ast
Disassembly and reassembly of ...... rion-like antibody reactivity.
@en
Disassembly and reassembly of ...... rion-like antibody reactivity.
@nl
type
label
Disassembly and reassembly of ...... rion-like antibody reactivity.
@ast
Disassembly and reassembly of ...... rion-like antibody reactivity.
@en
Disassembly and reassembly of ...... rion-like antibody reactivity.
@nl
prefLabel
Disassembly and reassembly of ...... rion-like antibody reactivity.
@ast
Disassembly and reassembly of ...... rion-like antibody reactivity.
@en
Disassembly and reassembly of ...... rion-like antibody reactivity.
@nl
P2093
P2860
P356
P1433
P1476
Disassembly and reassembly of ...... rion-like antibody reactivity.
@en
P2093
Clinton S Potter
Dave Wohlpart
Dicky Abraham
Jaime Alexandroff
Katrina High
Martha Brown
Mike Kosinski
Mike W Washabaugh
Qinjian Zhao
Robert D Sitrin
P2860
P356
10.1186/1743-422X-9-52
P577
2012-02-22T00:00:00Z